Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Onconova Announces Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Oral rigosertib progresses to phase 2 clinical trial in squamous cell head and neck cancers.

Onconova Therapeutics, Inc. announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented at the American Association for Cancer Research (AACR) Annual Meeting. The presentation was made by Antonio Jimeno, MD, PhD, of the University of Colorado School of Medicine and Director of the University’s Head and Neck Cancer Medical Oncology Program.

The oral presentation by Dr. Jimeno entitled, “Phase 1 and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors,” reported on the safety and activity of rigosertib in 48 patients. The objectives of this study were to define dose limiting toxicity, to characterize the pharmacokinetic (PK) profile, and to identify anti-tumor activity. Oral rigosertib was generally well tolerated. Notably, two of the six metastatic head and neck squamous cell carcinoma patients, with disease refractory to previous platinum-based therapy, showed anti-tumor responses. These responses included a confirmed complete response (CR) as well as a confirmed partial response (PR). These patients have received single-agent oral rigosertib for 98 and 48 weeks, respectively.

“The encouraging data reported today at AACR, describing the tolerability and clinical activity of oral rigosertib in advanced head and neck cancer, have driven the initiation of an 80-patient, multi-institutional nationwide Phase 2 trial in this patient population. Additionally, two Phase 2 trials, supported by proof of activity in earlier Phase 1 trials, are currently exploring utility of oral rigosertib in transfusion-dependent lower-risk MDS patients,” commented François Wilhelm, MD, PhD, Chief Medical Officer of Onconova. “We believe that these findings provide clinical support for further investigation of oral rigosertib as a treatment for advanced solid tumors, including metastatic head and neck cancer.”

Rigosertib has been extensively studied in clinical trials conducted in the U.S., Europe, Japan and India, in patients with solid tumors and blood cancers, with more than 850 patients enrolled in Phase 1, 2 and 3 trials, including a pivotal randomized Phase 3 trial conducted under a special protocol assessment (SPA) for patients with higher-risk myelodysplastic syndromes (MDS) previously treated with hypomethylating agents. Rigosertib, a patented new chemical entity, has received orphan designation for MDS and pancreatic cancer.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Onconova Appoints Ajay Bansal as Chief Financial Officer
Mr. Bansal has over 25 years of life sciences industry experience and most recently served as Chief Financial Officer at Complete Genomics.
Wednesday, April 03, 2013
Scientific News
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Tardigrade's Are DNA Master Thieves
Tardigrades, nearly microscopic animals that can survive the harshest of environments, including outer space, hold the record for the animal that has the most foreign DNA.
The Secret Behind the Power of Bacterial Sex
Migration between different communities of bacteria is the key to the type of gene transfer that can lead to the spread of traits such as antibiotic resistance, according to researchers at Oxford University.
Farming’s in Their DNA
Ancient genomes reveal natural selection in action.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos